Zyprexa News

Zyprexa Pulls Down Lilly's 4Q Sales
Eli Lilly reported fourth quarter 2011 adjusted earnings per share of 87 cents, 7 cents above the Zacks Consensus Estimate
Eli Lilly Profit Drops Sharply on Zyprexa Generics
Eli Lilly quarterly profit dropped 27 percent after its top-selling Zyprexa schizophrenia treatment lost U.S. patent protection and saw competition from generic rivals.
Zyprexa Pulls Down Lilly's 4Q Sales - Analyst Blog
Eli Lilly & Company ( LLY ) reported fourth quarter 2011 adjusted earnings per share of 87 cents, 7 cents above the Zacks Consensus Estimate but 24 cents below the year-ago
Earnings Preview: Lilly reports on 4Q results Tues
Eli Lilly and Co. will give investors on Tuesday its first quarterly earnings report since the drugmaker lost U.S. patent protection for its best-selling drug, the antipsychotic Zyprexa.
Lilly Tops Estimates as Cymbalta Sales Counter Zyprexa Drop
Eli Lilly & Co. reported fourth- quarter profit that beat analysts’ estimates as higher sales of its depression and diabetes medicines helped to counter a 44 percent plunge in revenue from the schizophrenia drug Zyprexa.
Lilly’s $4.5 Million Zyprexa Agreement With Health Providers Wins Approval
Eli Lilly & Co. won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper marketing of its best-selling medication Zyprexa raised their costs.
Lilly Reports Fourth-Quarter and Full-Year 2011 Results
INDIANAPOLIS, Jan. 31, 2012 /PRNewswire/ --Fourth quarter revenue declined two percent driven by Zyprexa and Gemzar patent expirations, partially offset by growth in other products.Fourth quarter earnings ...
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic ...
NEW YORK, Jan. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, ...
New product launches hold key for Dr Reddy's
Dr Reddy’s stellar performance for the quarter ending December (Q3) was led by the launch of an anti-psychotic drug, Olanzapine generics (Zyprexa brand) in the US on an exclusivity basis. The pharmaceutical services and active ingredients (PSAI) segment also provided a boost, as did Russian & CIS sales. While it is heartening that domestic sales growth touched a double-digit figure (11 per cent ...
Market Research: Antipsychotics Market Will Contract to $14 Billion by 2017
ROCKVILLE, MD-- - MarketResearch.com has announced the addition of the new report "Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic ...